StrokeDx Raises Oversubscribed $5 Million Seed Prime Round

0
147
Alexander Ballatori

PASADENA, Calif.– StrokeDx, a pioneer in next-generation stroke technology, today announced the successful closing of $5 million in Series Seed Prime funding. The oversubscribed round was led by DigiTx Partners, with participation by Freeflow Ventures and other existing investors with extensive accomplishments across neuroradiology, stroke, and medical devices. David J. Kim, MD, Managing Director of DigiTx Partners, will be joining the board. To date, StrokeDx’s technology has raised almost $10 million, including a National Institutes of Health (NIH) R01 Grant. This latest investment will support further clinical validation of StrokeDx’s groundbreaking technology and the expansion of its commercial efforts.

StrokeDx specializes in developing advanced technologies and software to enable portable, non-invasive, non-radiating cerebrovascular monitoring. The company’s innovative approach offers a unique and highly precise method to survey strokes using next-generation technology developed by Shane Shahrestani, MD, PhD, at the California Institute of Technology (Caltech).

The societal impact of StrokeDx’s technology is profound, offering a scalable solution to improve stroke outcomes for millions of at-risk individuals. By utilizing portable devices, StrokeDx addresses critical issues in healthcare accessibility and equity. Stroke remains a leading cause of death and disability worldwide, and early detection and rapid monitoring are key to improving survival rates and quality of life.

“Stroke affects millions globally, leading to significant mortality and long-term disability. This funding enables us to scale our detection and monitoring solution, empowering physicians and their patients with an effective tool for point-of-care cerebrovascular monitoring. Early intervention can significantly reduce the impact of stroke, shifting the focus from treatment to prevention,” said Alexander Ballatori, Co-Founder and CEO of StrokeDx.

“We believe in the potential of StrokeDx’s technology to change the diagnostic paradigm and ultimately improve outcomes for stroke patients. By providing accessible, advanced technology, we can reach millions of at-risk individuals, potentially saving countless lives and reducing the burden on healthcare systems around the world,” said David J. Kim, MD, Managing Director of DigiTx Partners.